Neoadjuvant olaparib
Phase 2Small molecule
Neoadjuvant olaparib is one of 42 small molecule programs targeting Treatment. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Dexilant
TakedaPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Theo-Dur
PfizerPreclinical
Levulan
Sun Pharmaceutical Industries, Inc.Preclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Clomid
FerringPreclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Neoadjuvant olaparib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHaukeland University Hospital